Slide 1: Q1 2024 Financial Results and Business Update
Q1 2024 Financial Results and Business Update 14 May 2024
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. 2
Slide 3: Speakers on Today's Call
Speakers on Today’s Call Hervé Brailly Sonia Quaratino Yannis Morel Arvind Sood PhD MD, PhD PhD Chief Executive Officer ad Chief Medical Officer Chief Operating Officer President of US Operations interim Chairman of the Executive Board 3
Slide 4: Scientific innovation drives our strategy
Scientific innovation drives our strategy Lacutamab ANKET® & ADC Monalizumab Our ambition – leverage our scientific know-how in innate IPH6501 at ASCO Phase 2 MF at Phase 3 trial immunity and antibody engineering to IPH45 ADC at AACR ASCO, Continue to underway, further develop cancer drugs that impr
Slide 5: Lacutamab, IPH6501, SAR'579 and other programs by mechanism
Lacutamab (KIR3DL2) IPH6501 (CD20-IL2v) SAR’579, IPH6101 (CD123) SAR’514, IPH6401 (BCMA) IPH62 (B7H3) IPH67 Monalizumab (NKG2A) IPH5201 (CD39) IPH5301 (CD73) Modified from Vivier et al., Nature February 2024 5
Slide 6: Our robust pipeline of proprietary & partnered assets
Our robust pipeline of proprietary & partnered assets Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Comments Lacutamab KIR3DL2 Sezary syndrome / MF Phase 2 TELLOMAK (FDA FAST TRACK/EMA PRIME DESIGNATION) MF data ASCO 2024 Monoclonal antibodies PTCL Phase 2 KILT IST with LYSA IPH5301
Slide 7: Five abstracts selected for ASCO 2024
Five abstracts selected for ASCO 2024 IPH6501 Lacutamab Monalizumab IL2v-armed Tetra-specific Anti KIR3DL2 mAb Anti NKG2A mAb ANKET® targeting CD20 Phase 2 TELLOMAK Phase 1/2 Phase 2 COAST Trial-In-Progress Updated Phase 2 results Top-line phase 2 results IPH6501 in R/R CD20-expressing Durvalumab ±
Slide 8: Lacutamab | Clinical Trials
LACUTAMAB Lacutamab | Clinical Trials A potential new standard of care in the T-cell lymphomas expressing KIR3DL2 Cutaneous T cell lymphoma TELLOMAK Sézary syndrome Phase 2 Trial Sézary syndrome 80-200 patients Phase 2 >90% KIR3DL2 expression N=56 N~100 ASH 2023 Minimum of 2 prior Cohort 2 Cohort 3
Slide 9: IPH6501, a novel CD20-targeting tetraspecific NK cell engager
ANKET® IPH6501, a novel CD20-targeting tetraspecific natural killer cell engager issued from ANKET® platform, has started clinical study in B-cell malignancies IPH6501, the first proprietary tetraspecific ANKET® Phase 1/2 first-in-human, multicenter, in Patients With Relapsed and/or Refractory Non-H
Slide 10: Multiple ANKET programs targeting hematological malignancies and solid tumors
ANKET® Multiple ANKET® programs targeting hematological malignancies and solid tumors SAR443579 progress to Phase 2 Growing clinical pipeline SAR443579 progress to Ph2 SAR443579 / IPH6101 (CD123) Phase 2 • Clinical PoC established in Phase 1/2 in R/R AML with complete and durable responses in monoth
Slide 11: Leveraging antibody expertise by developing differentiated ADCs
ADC We are leveraging our antibody expertise by developing differentiated ADCs ADC Research pipeline – Lead asset at pre-IND stage IPH45 (Nectin-4) Pre-IND IPH43 (MICA/B) Phase 1 Research Target (Tumor antigen) Research Target (Celiac disease) Research
Slide 12: IPH45 is a novel and differentiated Nectin-4 DAR8 exatecan ADC
ADC IPH45 is a novel and differentiated Nectin-4 DAR8 exatecan ADC Progress towards IND in 2024 Binder Payload Exatecan, Proprietary humanized a Topoisomerase I inhibitor anti-Nectin-4 Antibody • Active in EV/MMAE-resistant models • High affinity • Higher Bystander Effect than EV, leading to stronge
Slide 13: IPH45 has potential for improved clinical benefits across multiple tumor types
ADC IPH45 has potential for improved clinical benefits across multiple tumor types Stronger preclinical efficacy than EV with higher bystander effect Packages IND in 2024 H-score 120 H-score 300 • Stronger efficacy than EV Nectin-4 expression in low Nectin-4 PDX Productivity with high models of UC t
Slide 14: Monalizumab development in progress of Phases 2 and 3 trials
MONALIZUMAB Monalizumab development in progress of Phases 2 and 3 trials Covering early stages of lung cancer Stages of the disease NeoCOAST* Data presented: 2022 NeoCOAST-2* 30% major pathological Patients with Stage II to IIIB NSCLC NSCLC response vs. 11% durvalumab. Monalizumab + durvalumab + che
Slide 15: Newsflow and upcoming catalysts
Newsflow and upcoming catalysts • Monalizumab PACIFIC-9 | Phase 3 readout (AZ) Delivering across our strategic objectives • Monalizumab NeoCOAST-2 | Phase 2 readout (AZ) • IPH5201 (CD39) MATISSE | Phase 2 readout (AZ) • IPH5301 (CD73) | Phase 1 data • SAR’579 / IPH6101 ANKET® (CD123) | Next steps (S
Slide 16: Key Takeaways
Key Takeaways Create value for patients and shareholders Established expertise in immuno-pharmacology • LACUTAMAB TELLOMAK DATA • Top-line results in mycosis fungoides to be shared at ASCO • Regulatory strategy • EXPAND ANKET® CLINICAL PORTFOLIO – LEAD IN HEMATOLOGY INDICATIONS • First patient dosed
Slide 17: Thank you
Thank you www.innate-pharma.com investors@innate-pharma.fr EURONEXT : IPH.PA NASDAQ : IPHA